Evaluation of the Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Expression in Osteosarcoma and Its Association with the Clinicopathological Data

BACKGROUND: The receptor activator of nuclear factor kappa B ligand (RANKL) is one of the key regulators of bone remodelling in bone oncology, including osteosarcoma. We assessed RANKL immunohistochemical expression in osteosarcoma, its association, and disease-free survival with the patients’ clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Hui Heng, Tuan Sharif, Sharifah Emilia, Wan Ismail, Wan Faisham Nu’man, Zawawi, Muhamad Syahrul Fitri, Abdullah, Sarimah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286667/
https://www.ncbi.nlm.nih.gov/pubmed/33773537
http://dx.doi.org/10.31557/APJCP.2021.22.3.741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286667/
https://www.ncbi.nlm.nih.gov/pubmed/33773537
http://dx.doi.org/10.31557/APJCP.2021.22.3.741

Ejemplares similares